摘要
目的探析重组人促红细胞生成素注射液治疗肾性贫血的临床疗效。方法选择研究对象是2012年7月~2014年7月就诊的60例肾性贫血患者,分为两组,分别给予常规腹膜透析与常规腹膜透析＋重组人促红细胞生成素注射液进行治疗,对比两组患者的临床疗效。结果观察组患者的治疗有效率是96.7%,对照组是80%,差异性显著（P〈0.05）。观察组患者的不良反应发生率是6.7%,对照组中未见不良反应,无显著差异性（P〉0.05）。治疗前,观察组患者的血红蛋白与红细胞压积分别是（70.3±9.2）g/L、（23.2±5.1）%,对照组是（70.3±10.3）g/L、（23.2±4.1）%,两组患者无显著差异性（P〉0.05）。治疗后,观察组是（99.4±11.1）g/L、（32.3±2.9）%,对照组是（91.3±11.4）g/L、（28.2±4.1）%,差异性显著（P〈0.05）。结论肾性贫血患者的临床治疗中使用重组人促红细胞生成素注射液,极大的改善患者的贫血表现,提高临床疗效,快速增加患者体内的红细胞压积与血红蛋白,且不良反应发生率较低。
Objective To study the clinical effect of recombinant human erythropoietin injection in the treatment of renal anemia. Methods 60 patients with renal anemia in our hospital from July 2012 to July 2014 were divided into two groups,which were treated with conventional peritoneal dialysis and conventional peritoneal dialysis plus recombinant human erythropoietin injection. The clinical efficacy of the two groups were compared. Results the effective rate of the observation group was 96. 7%,the control group was 80%,the difference was significant（ P〈0. 05）. Conclusions The use of recombinant human erythropoietin injection in the treatment of patients with renal anemia,greatly improving the patient＇s anemia performance,improve the clinical efficacy,rapid increase in patients with blood pressure and hemoglobin,and the incidence of adverse reactions is lower.
出处
《航空航天医学杂志》
2016年第2期149-150,共2页
Journal of Aerospace medicine
